Literature DB >> 6606432

Decrease of the OKT8 positive T cell subset in polymyalgia rheumatica. Lack of correlation with disease activity.

C Benlahrache, P Segond, L Auquier, J P Bouvet.   

Abstract

Peripheral T cell populations were investigated in 35 patients suffering from polymyalgia rheumatica. The total number of T cells was low compared with those of a control group of similar age (P less than 10(-3). This decrease was demonstrated by using both classic E-rosette and monoclonal antibody techniques (OKT3, and OKT4 + OKT8) and was shown to be secondary to a selective T8 defect (P less than 10(-9). There was no correlation between the decrease in T8 (a cytotoxic suppressor T cell subset) and steroid therapy, disease activity, and temporal arteritis, nor between this decrease and the T gamma percentage and the presence of circulating immune complexes (CIC). The T gamma cell percentage was low in the patient group (P less than 10(-5) and correlated with the presence of detectable CIC (P less than 0.05). In contrast to the T8 and T gamma defects, concanavalin A-stimulated cells from 5 selected patients were found capable of suppressing in vitro anti-trinitrophenyl response. This suppression was found in both autologous and allogeneic experiments. From these data one can assume that an immune anomaly (T8 defect) could be the origin of CIC and the disease occurrence.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6606432     DOI: 10.1002/art.1780261209

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  12 in total

Review 1.  Stopping steroids in polymyalgia rheumatica and giant cell arteritis.

Authors:  V Kyle; B L Hazelman
Journal:  BMJ       Date:  1990-02-10

2.  Selective depletion and activation of CD8+ lymphocytes from peripheral blood of patients with polymyalgia rheumatica and giant cell arteritis.

Authors:  B Dasgupta; O Duke; A M Timms; C Pitzalis; G S Panayi
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

3.  A seasonal pattern in the onset of polymyalgia rheumatica.

Authors:  M A Cimmino; R Caporali; C M Montecucco; S Rovida; E Baratelli; M Broggini
Journal:  Ann Rheum Dis       Date:  1990-07       Impact factor: 19.103

4.  Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study.

Authors:  B Dasgupta; O Duke; V Kyle; D G Macfarlane; B L Hazleman; G S Panayi
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

5.  T cell subsets and expression of immunological activation markers in the arterial walls of patients with giant cell arteritis.

Authors:  R Andersson; R Jonsson; A Tarkowski; B A Bengtsson; B E Malmvall
Journal:  Ann Rheum Dis       Date:  1987-12       Impact factor: 19.103

6.  Peripheral blood lymphocyte subsets in polymyalgia rheumatica.

Authors:  A Uddhammar; G Roos; B Näsman; S R Dahlqvist
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980

7.  Circulating T cell subtypes in polymyalgia rheumatica and giant cell arteritis: variation in the percentage of CD8+ cells with prednisolone treatment.

Authors:  G D Pountain; M T Keogan; D L Brown; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1993-10       Impact factor: 19.103

8.  T lymphocytes in giant cell arteritic lesions are polyclonal cells expressing alpha beta type antigen receptors and VLA-1 integrin receptors.

Authors:  C Schaufelberger; S Stemme; R Andersson; G K Hansson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

9.  The Cambridge dilemma.

Authors:  P Elling; H Elling; A T Olsson
Journal:  Ann Rheum Dis       Date:  1994-11       Impact factor: 19.103

10.  Treatment of polymyalgia rheumatica with intramuscular injections of depot methylprednisolone.

Authors:  B Dasgupta; J Gray; L Fernandes; C Olliff
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.